{"altmetric_id":16808837,"counts":{"readers":{"mendeley":0,"citeulike":0,"connotea":0},"total":{"posts_count":9},"news":{"unique_users_count":8,"unique_users":["business_wire","digital_journal","wall_street_online_denmark","yahoo_finance_usa","ariva","nasdaq","biomed_reports","bioportfolio"],"posts_count":9}},"citation":{"altmetric_jid":"4f6fa61f3cf058f610007b59","authors":["Stacie M. Jones","Brian P. Vickery","J. Andrew Bird","Jonathan M. Spergel","Rima A. Rachid","Amal H. Assa'ad","Julie Wang","Stephanie A. Leonard","Susan Stefanac Laubach","Edwin Kim","Benjamin P. Davis","Michael Welch","Jennifer Heimall","Antonella Cianferoni","Andrew J. MacGinnitie","Elena Crestani","Amr Radwan","Andrea Vereda","Daniel C. Adelman","A. Wesley Burks"],"doi":"10.1016\/j.jaci.2016.12.824","first_seen_on":"2017-02-27T13:52:06+00:00","issns":["00916749"],"journal":"The Journal of Allergy and Clinical Immunology","last_mentioned_on":1488201811,"links":["http:\/\/www.jacionline.org\/article\/S0091-6749(16)32342-9\/pdf","http:\/\/www.jacionline.org\/article\/S0091-6749(16)32342-9\/pdf.Abstract"],"pubdate":"2017-02-01T00:00:00+00:00","publisher_subjects":[{"name":"Immunology","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Immunology and Microbiology"],"title":"At-home Dosing Adherence During Characterized Oral Desensitization Immunotherapy (CODIT) for Peanut Allergy","type":"article","uri":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674916323429"},"altmetric_score":{"score":62,"score_history":{"1y":62,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":62},"context_for_score":{"all":{"total_number_of_other_articles":8282830,"mean":6.9841686085689,"rank":146383,"this_scored_higher_than_pct":98,"this_scored_higher_than":8136329,"rank_type":"exact","sample_size":8282830,"percentile":98},"similar_age_3m":{"total_number_of_other_articles":242396,"mean":13.659301685265,"rank":10248,"this_scored_higher_than_pct":95,"this_scored_higher_than":232137,"rank_type":"exact","sample_size":242396,"percentile":95},"this_journal":{"total_number_of_other_articles":5109,"mean":13.56911981206,"rank":186,"this_scored_higher_than_pct":96,"this_scored_higher_than":4921,"rank_type":"exact","sample_size":5109,"percentile":96},"similar_age_this_journal_3m":{"total_number_of_other_articles":162,"mean":70.771428571429,"rank":35,"this_scored_higher_than_pct":77,"this_scored_higher_than":125,"rank_type":"exact","sample_size":162,"percentile":77}}},"demographics":[],"posts":{"news":[{"title":"Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting","url":"http:\/\/ct.moreover.com\/?a=29724915983&p=1pl&v=1&x=ooqxHDViyyBbk9UpF6ceZg","license":"public","citation_ids":[16808837,16808838,16808839],"posted_on":"2017-02-27T13:00:00+00:00","summary":"BRISBANE, Calif.--( BUSINESS WIRE )--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT\u2122 ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced\u2026","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting - Press Release","url":"http:\/\/ct.moreover.com\/?a=29724910590&p=1pl&v=1&x=zTcooR5yCAnlDfp7hQO5Xw","license":"public","citation_ids":[16808837,16808838,16808839,16808837,16808838,16808839],"posted_on":"2017-02-27T13:06:19+00:00","summary":"\u0001BRISBANE, Calif.--(Business Wire)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT\u2122 ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced\u2026","author":{"name":"Digital Journal","url":"http:\/\/www.digitaljournal.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/223\/normal\/image.png?1371424893"}},{"title":"Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting","url":"http:\/\/ct.moreover.com\/?a=29724956955&p=1pl&v=1&x=Z2d44SBP_MuvA9Pn3kQH2A","license":"public","citation_ids":[16808837,16808838,16808839],"posted_on":"2017-02-27T13:11:01+00:00","summary":"Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT\u2122 ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that new clinical data on AR101 will be\u2026","author":{"name":"Wall Street Online Denmark","url":"http:\/\/www.wallstreet-online.de","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/836\/normal\/Screen_Shot_2016-01-27_at_11.09.05.png?1453892964"}},{"title":"Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting","url":"http:\/\/ct.moreover.com\/?a=29724979763&p=1pl&v=1&x=ZM7qV1DDlC00oQmPr5j9bA","license":"public","citation_ids":[16808837,16808838,16808839],"posted_on":"2017-02-27T13:00:00+00:00","summary":"BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. ( AIMT ), a biopharmaceutical company developing CODIT\u2122 ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that new\u2026","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting","url":"http:\/\/ct.moreover.com\/?a=29724993695&p=1pl&v=1&x=ciYI8j_E_WOTzmMrovotRg","license":"public","citation_ids":[16808837,16808838,16808839,16808837,16808838,16808839],"posted_on":"2017-02-27T13:14:43+00:00","summary":"BRISBANE, Calif. --(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT\u2122 (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that new\u2026","author":{"name":"Ariva","url":"http:\/\/www.ariva.de","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/907\/normal\/Screen_Shot_2016-01-27_at_14.41.07.png?1453905685"}},{"title":"Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of \u2026","url":"http:\/\/ct.moreover.com\/?a=29724994107&p=1pl&v=1&x=H6xlERrCesCHQXChLTCV-g","license":"public","citation_ids":[16808837,16808838,16808839,16808837,16808838,16808839],"posted_on":"2017-02-27T13:14:45+00:00","summary":"BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing CODIT\u2122 (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that new clinical\u2026","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting","url":"http:\/\/ct.moreover.com\/?a=29725016897&p=1pl&v=1&x=2qu2TLDCCulu17mfiD8PXQ","license":"public","citation_ids":[16808837,16808838,16808839,16808837,16808838,16808839],"posted_on":"2017-02-27T01:00:00+00:00","summary":"BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT\u2122 (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that new\u2026","author":{"name":"NASDAQ","url":"http:\/\/www.nasdaq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/839\/normal\/Screen_Shot_2016-01-27_at_11.14.52.png?1453893369"}},{"title":"Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting","url":"http:\/\/ct.moreover.com\/?a=29725079079&p=1pl&v=1&x=3VKAPiEkVO2JUczeskcbmA","license":"public","citation_ids":[16808837,16808838,16808839],"posted_on":"2017-02-27T13:23:31+00:00","summary":"Feb. 27, 2017 13:00 UTC BRISBANE, Calif.--( BUSINESS WIRE )-- Aimmune Therapeutics, Inc.","author":{"name":"BioMed Reports","url":"http:\/\/www.biomedreports.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/913\/normal\/Screen_Shot_2016-02-02_at_15.18.15.png?1454426307"}},{"title":"Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting","url":"http:\/\/ct.moreover.com\/?a=29725209778&p=1pl&v=1&x=q5P2fmXXxbTForNNn_GxPw","license":"public","citation_ids":[16808837,16808838,16808839,16808837,16808838,16808839],"posted_on":"2017-02-27T13:00:00+00:00","summary":"Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT\u2122 (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that new clinical data on AR101 will be\u2026","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}}]}}